To provide surgeons with optimal guidance during interventions, it is crucial that the molecular imaging data generated in the diagnostic departments finds its way to the operating room. Sentinel lymph node (SLN) biopsy provides a textbook example in which molecular imaging data acquired in the department of nuclear medicine guides the surgical management of patients. For prostate cancer, in which SLNs are generally located deep in the pelvis, procedures are preferably performed via a (robotassisted) laparoscopic approach. Unfortunately, in the laparoscopic setting the senses of the surgeon are reduced. This topical review discusses technologic innovations that can help improve surgical guidance during SLN biopsy procedures. Metastasis in pelvic lymph nodes (LNs) is considered an important prognostic factor in prostate cancer. Prostatespecific antigen levels, pathologic stage, and Gleason score are predictors for LN involvement; the higher these factors are, the greater is the chance of nodal involvement. Postoperative (histo)pathologic examination of tissue samples obtained during (extended) pelvic lymphadenectomy is considered the gold standard in assessing metastatic spread. With an increasing LN dissection template, the prognosis of both N0 and N1 groups increases (Will Rogers phenomenon). Unfortunately, (extended) pelvic lymphadenectomy also increases the chance of postoperative complications such as lymphoceles, injuries to the obturator nerve or the ureter, and lymphedema of the lower extremity. Such complications can lead to a decrease in the patient's quality of life.Sentinel LN (SLN) biopsy focuses on the identification, subsequent minimally invasive excision, and pathologic and histopathologic evaluation of the LNs that drain directly from the primary tumor. Assuming the orderly spread of tumor cells through the lymphatic system, SLN biopsy can be used for LN staging. After staging, therapeutic follow-up can be decided on.The potential of SLN biopsy for detecting LN metastasis has been validated in several studies. The Augsburg group validated the SLN biopsy procedure in more than 2,000 patients with prostate cancer and reported a high sensitivity and an overall false-negative rate of 5.9% (1). Moreover, SLN biopsy allows the identification of SLNs outside the pelvic lymphadenectomy field (2-4). Recently, Joniau et al. showed that 44% of SLNs were located outside the extended pelvic lymphadenectomy field; in 6% of patients, a positive LN was located exclusively in the presacral or paraaortic region (2).Ideally, a surgeon is able to identify and excise the preoperatively identified SLNs in a minimally invasive manner, with a high sensitivity and specificity. This topical review discusses technologic improvements that may help improve the different aspects involved in (robot-assisted) laparoscopic SLN biopsy for prostate cancer; SLN biopsy for the prostate is often performed in combination with laparoscopic radical prostatectomy. Potential improvements can be found in (hybrid) tracers that are radioacti...